Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA
Open Access
- 4 March 2026
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (4) , 367-381
Abstract
The traditional immunogenicity paradigm resulting in anti-drug antibody (ADA) and neutralizing antibody (NAb) positive/negative status and ambiguous or imprecise titers may overlook clinically relevant effects of ADA on pharmacokinetics (PK) and pharmacodynamics (PD). Employing risk-based strategies that integrate PK and PD analyses with ADA magnitude using signal-to-noise (S/N) can provide early insight into potential clinical impact of immunogenicity. In a Phase 1 evaluation of DLX-2323, a humanized single-chain variable fragment (scFv) antibody that binds human IL-1β, ADA-sensitive PK and PD assays were employed to measure DLX-2323 concentration, PD activity, and assess the impact of ADA on PK and PD in healthy participants. The presence of pre-existing ADA was observed in one-third of participants and resulted in high variability of DLX-2323 exposure and PD activity. Pre-existing ADA magnitude correlated with a drug-sustaining impact on PK and PD, with lower clearance (CL/F) and volume of distribution (Vd/F) of DLX-2323 relative to increasing ADA signal. Based on the immunogenicity risk assessment, the use of ADA-sensitive free PK and PD assays to measure in vivo ADA effects on drug exposure and PD activity provided clinically meaningful information that standalone neutralizing antibody assays could not.Keywords
Funding Information
- Immunologix
- Arrivo Bioventures
This publication has 41 references indexed in Scilit:
- Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry ApproachJournal of Proteome Research, 2019
- Habit Modification of the Active Pharmaceutical Ingredient Lovastatin Through a Predictive Solvent Selection ApproachJournal of Pharmaceutical Sciences, 2019
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer diseaseNature Reviews Neurology, 2019
- Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeuticsJournal of Pharmaceutical and Biomedical Analysis, 2011
- Phosphodiesterases reduce spontaneous sinoatrial beating but not the ‘fight or flight’ tachycardia elicited by agonists through Gs-protein-coupled receptorsTrends in Pharmacological Sciences, 2011
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upJAMA, 2011
- Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeuticsClinical Immunology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- 'Human' insulin versus animal insulin in people with diabetes mellitusCochrane Database of Systematic Reviews, 2005
- Development of human anti‐murine antibody (HAMA) response in patientsImmunology & Cell Biology, 1990